Skip to main content
Have a personal or library account? Click to login
Osteoporosis Treatment Gap — A Systematic Literature Review Cover

Osteoporosis Treatment Gap — A Systematic Literature Review

Open Access
|Sep 2026

Figures & Tables

Figure 1:

PRISMA 2020 flow diagram (7) representing the selection of 43 (20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62) original research studies included in the systematic review.

Table 1:

Overview of patient-related (demographic and clinical), physician-related, system-level, and organisational factors associated with variations in osteoporosis treatment rate (20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62).

DimensionsFactors contributing to lower treatment ratesFactors contributing to higher treatment rates
Patient-level factors (demographic and clinical)Patient Demographics
Social History
  • Lower socio-economic status (40, 61)

  • Lower education levels (23)

  • Lower annual income (49)

  • Socioeconomically disadvantaged residential areas (40)

  • Current tobacco use (34)

  • Married status (49)

Family History
  • Family history of osteoporosis or fragility fractures (31, 51)

Fracture Type
  • No documented previous fragility fractures (31)

  • Non-vertebral fractures (2627, 33, 58, 61)

  • Non-major osteoporotic fracture (21, 37)

Past Medical History and Investigations
  • Dementia (22, 33)

  • Diabetes (28, 31, 38)

  • Chronic liver disease (28)

  • Chronic kidney disease (28, 33, 62)

  • Cardiovascular disease and hypertension (28, 38)

  • Arthritis (34)

  • Gastrointestinal troubles (38)

  • Comorbidity (20, 45, 60), high Charlson comorbidity index score (23, 33, 58)

  • Rheumatoid arthritis and systemic lupus (28, 51)

  • Diagnosis of osteoporosis or bone mineral density testing before a fragility fracture (21, 29, 36, 4344, 48, 58)

  • Low bone mineral density score (25, 41)

Pharmacotherapy
  • Polypharmacy (26, 45, 57)

  • Oestrogen-only hormone replacement therapy (28)

  • Corticosteroids (28, 51, 58)

  • Prior vitamin D and calcium prescriptions (41)

Economic Factors
  • Cost of treatment (49, 54, 60)

Patient Belief & Behaviour
  • Low adherence (47)

  • Refusal of treatment (60)

  • Belief that osteoporosis is not serious (49)

  • More frequent doctor visits (51)

Healthcare professionals and healthcare system-level factorsPhysician-related factors
  • Lack of osteoporosis awareness (54)

  • Limited familiarity with treatment (47, 53)

  • Fear of anti-osteoporotic medications side effects (as perceived barrier by physicians) (54, 60)

  • Workload concerns (53)

  • Differences in prescription practices (46, 6162)

  • Differences in referral practices (62)

  • Risk assessment not routine practice (44, 47, 55)

  • Failure to investigate (47, 56)

  • Knowledge gaps and lack of confidence (53)

  • Lack of comfort with making treatment changes (60)

  • Intentions to modify the treatment plan (60)

  • Disagreement with recommendations (60), reservations about protocol-based approaches (53)

  • Preference for Fracture Liaison Service (FLS) programmes over standard care (53)

  • Perception by general practitioners that preventive therapy is a specialist's responsibility (57)

  • Interprofessional communication issues and role ambiguity (44, 59)

  • Belief that the current care plan was appropriate (60)

  • Specialist-prescribed treatment plans limiting other providers’ interventions (60)

Both physician and system-related factors:
  • Transfer to a rehabilitation (42) or a geriatric unit (42)

  • Preference for FLS (53)

System/Institutional factors
  • Lack of patient education and awareness (44, 49, 55, 59)

  • Long intervals between fracture and outpatient visit (25)

  • Length of hospital stay (42)

  • Bone-strengthening or community-based physical activity programmes rare (55)

Table 2:

Country-wise summary of treatment gap estimates in included studies (20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41, 43,44,45,46,47,48, 5152, 56, 58, 60,61,62).

Author & YearCountryTreatment Gap EstimateTreatment Gap Type*Author & YearCountryTreatment Gap EstimateTreatment Gap Type*
Feldstein 2005 (58)USA84% (post-hip or vertebral fracture)Post-fracture secondary preventionLeslie 2020 (61)Canada77.1% of cancer patients and 78.2% of non-cancer patientsPost-fracture secondary prevention
Papaioannou 2008 (43)Canada90%Post-fracture secondary preventionMcCloskey 2020 (48)Belgium, France, Germany, Ireland, Poland, Slovakia, UK74.6% (varying from 53% in Ireland to 91% in Germany)Osteoporosis/high-risk population
Bessette 2009 (41)Canada84%Post-fracture secondary preventionSkjødt 2020 (30)Denmark, Spain (Catalonia), UKDenmark: 88–90% (2005–2014)Post-fracture secondary prevention
Curtis 2009 (52)USA74% even among the highest risk group (Caucasian men with prior fracture)Osteoporosis/high-risk populationMalle 2021 (47)Austria82% in women, 92% in menPost-fracture secondary prevention
Leslie 2011 (40)Canada93.9% in 1996/1997, 87.7% in 2001/2002, 94.1% in 2007/2008Post-fracture secondary preventionNakatoh 2021 (26)Japan68.4% (hip fracture), 38.3% (vertebral fracture)Post-fracture secondary prevention
Leslie 2012 (39)Canada94.6% in First Nations peoples vs 87.5% in non-IndigenousPost-fracture secondary preventionPapaioannou 2021 (60)Canada63%Osteoporosis/high-risk population
Roux 2013 (37)Canada81.2% in the standard care groupPost-fracture secondary preventionSkjødt 2021 (27)Denmark85% (2005), 79% (2014)Post-fracture secondary prevention
Siris 2013 (38)USA64.3%Osteoporosis/high-risk populationWalsh 2021 (28)Ireland79%Osteoporosis/high-risk population
Cunningham 2014 (51)USA38.8%Osteoporosis/high-risk populationHoit 2022 (24)USA74% (30 days after operation)Post-fracture secondary prevention
Yusuf 2016 (36)USA85.1%Post-fracture secondary preventionMartinez-Laguna 2022 (45)Spain56.8%Post-fracture secondary prevention
Gani 2017 (32)Singapore68.5%Post-fracture secondary preventionWu 2022 (25)Taiwan64.4%Post-fracture secondary prevention
Keshishian 2017 (33)USA72.2%Post-fracture secondary preventionYavropoulou 2022 (46)Greece58%Osteoporosis/high-risk population
Mendis 2017 (56)Australia87%Post-fracture secondary preventionBliuc 2023 (20)Australia78% (women), 86% (men)Post-fracture secondary prevention
Sattari 2017 (34)USA78.4%Osteoporosis/high-risk populationCheah 2023 (21)Malaysia82.9%Post-fracture secondary prevention
Wang 2017 (35)Taiwan> 60% for women, 90% for menOsteoporosis/high-risk populationEl Miedany 2023 (44)Egypt82.1%Post-fracture secondary prevention
Cheung 2018 (62)Hong KongFrom 91% to 85% between 2009 and 2012Post-fracture secondary preventionFujii 2023 (22)Japan60%Post-fracture secondary prevention
Bougioukli 2019 (31)Greece78.6%Post-fracture secondary preventionMahaisavariya 2023 (23)Thailand68.4%Post-fracture secondary prevention
Iconaru 2020 (29)Belgium74.6%–76.5%Post-fracture secondary prevention

* Post-fracture secondary prevention refers to treatment eligibility assessed following a fragility fracture. Osteoporosis/high-risk population refers to individuals identified through osteoporosis diagnosis, low bone mineral density, fracture-risk assessment tools (FRAX or CAROC), or population-based estimates of osteoporosis prevalence.

Figure 2:

Geographical distribution of included studies (20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62).

DOI: https://doi.org/10.2478/sjph-2026-0022 | Journal eISSN: 1854-2476 | Journal ISSN: 0351-0026
Language: English, Polish, Slovenian
Page range: 184 - 196
Submitted on: Oct 30, 2025
Accepted on: Jun 3, 2026
Published on: Sep 1, 2026
Published by: National Institute of Public Health, Slovenia
In partnership with: Paradigm Publishing Services

© 2026 Kaja Gril Rogina, Luka Petravič, Christos Oikonomidis, published by National Institute of Public Health, Slovenia
This work is licensed under the Creative Commons Attribution 4.0 License.